Quest Diagnostics

Report Status: Final

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Phone: Patient ID:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	

COMMENTS: FASTING:YES

Test Name	In Range	Out Of Range	Reference Range	Lab
FSH	7.8		mIU/mL	

Reference Range

Follicular Phase	2.5-10.2
Mid-cycle Peak	3.1-17.7
Luteal Phase	1.5- 9.1
Postmenopausal	23.0-116.3

LH	3.4		mIU/mL	

Reference Range

Follicular Phase	1.9-12.5
Mid-Cycle Peak	8.7-76.3
Luteal Phase	0.5-16.9
Postmenopausal	10.0-54.7

ESTRADIOL	36		pg/mL	

Reference Range

Follicular Phase:	19-144
Mid-Cycle:	64-357
Luteal Phase:	56-214
Postmenopausal:	< or = 31

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.

ANTI-MULLERIAN HORMONE (AMH), FEMALE	1.47		0.18-5.68 ng/mL	

REFERENCE RANGE for AMH, FEMALE

Age	Males (ng/mL)	Females (ng/mL)
0 - 17 Years		Not Established
18 - 25 Years		1.02 - 14.63
26 - 30 Years		0.69 - 13.39
31 - 35 Years		0.36 - 10.07
36 - 40 Years		0.18 - 5.68
41 - 45 Years		0.01 - 2.99

Valencia has transitioned to the FDA approved Beckman Access AMH

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab

assay. For physicians monitoring patients, please note that the reference ranges have changed. A new baseline may need to be established.

PERFORMING SITE: